The US Hemp Roundtable is  the hemp industry’s national business association that represents over thirty firms and organizations across the country – at each link of the hemp supply and sales chain – as well as all of its major national grassroots organizations, submitted its formal comments yesterday.

In sum, the Roundtable strongly recommends against the scheduling of hemp-derived CBD as an international controlled substance.

The Roundtable argues that CBD derived from hemp is not a controlled substance and has many medicinal and non-medicinal uses.

It further urges FDA to include in its evaluation the evidence demonstrating the low abuse and dependence potential, safety, and health benefits of hemp-derived CBD – all of which were recognized by WHO in its recent report on CBD and have been confirmed by the totality of scientific evidence.

Here is their full submission

US-Hemp-Roundtable_-FDA-WHO-Comments_4.23.2018